메뉴 건너뛰기




Volumn 34, Issue 18, 2005, Pages 1315-1324

Preventing cerebrovascular accidents during atrial fibrillation;Prévention des accidents vasculaires cérébraux dans la fibrillation auriculaire

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDRAPARINUX; PLACEBO; STATINE DERIVATIVE; WARFARIN; XIMELAGATRAN;

EID: 27544465406     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84180-6     Document Type: Short Survey
Times cited : (5)

References (70)
  • 1
    • 0017900027 scopus 로고
    • Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study
    • Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-7.
    • (1978) Neurology , vol.28 , pp. 973-977
    • Wolf, P.A.1    Dawber, T.R.2    Thomas Jr., H.E.3    Kannel, W.B.4
  • 3
    • 0026543430 scopus 로고
    • Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk
    • The Stroke Prevention in Atrial Fibrillation Investigators
    • Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 1-5.
    • (1992) Ann Intern Med , vol.116 , pp. 1-5
  • 5
    • 0028882469 scopus 로고
    • Does atrial fibrillation confer a hypercoagulable state?
    • Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346: 1313-14.
    • (1995) Lancet , vol.346 , pp. 1313-1314
    • Lip, G.Y.1
  • 6
    • 0032779161 scopus 로고    scopus 로고
    • Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)
    • Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1080-7.
    • (1999) J Am Soc Echocardiogr , vol.12 , pp. 1080-1087
    • Goldman, M.E.1    Pearce, L.A.2    Hart, R.G.3    Zabalgoitia, M.4    Asinger, R.W.5    Safford, R.6    Halperin, J.L.7
  • 7
    • 0032803662 scopus 로고    scopus 로고
    • Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study)
    • Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999; 12: 1088-96.
    • (1999) J Am Soc Echocardiogr , vol.12 , pp. 1088-1096
    • Asinger, R.W.1    Koehler, J.2    Pearce, L.A.3    Zabalgoitia, M.4    Blackshear, J.L.5    Fenster, P.E.6
  • 8
    • 0031747445 scopus 로고    scopus 로고
    • Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation
    • Stroke Prevention in Atrial Fibrillation III Investigators
    • Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31: 1622-6.
    • (1998) J Am Coll Cardiol , vol.31 , pp. 1622-1626
    • Zabalgoitia, M.1    Halperin, J.L.2    Pearce, L.A.3    Blackshear, J.L.4    Asinger, R.W.5    Hart, R.G.6
  • 10
    • 0026599354 scopus 로고
    • Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk
    • The Stroke Prevention in Atrial Fibrillation Investigators
    • Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116: 6-12.
    • (1992) Ann Intern Med , vol.116 , pp. 6-12
  • 11
    • 0038417537 scopus 로고    scopus 로고
    • Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation
    • Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107: 3141-5.
    • (2003) Circulation , vol.107 , pp. 3141-3145
    • Conway, D.S.1    Pearce, L.A.2    Chin, B.S.3    Hart, R.G.4    Lip, G.Y.5
  • 12
    • 4644309097 scopus 로고    scopus 로고
    • Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    • Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 429S-456S.
    • (2004) Chest , vol.126
    • Singer, D.E.1    Albers, G.W.2    Dalen, J.E.3    Go, A.S.4    Halperin, J.L.5    Manning, W.J.6
  • 13
    • 0028244264 scopus 로고
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
    • (1994) Arch Intern Med , vol.154 , pp. 1449-1457
  • 14
    • 0033063754 scopus 로고    scopus 로고
    • Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials
    • The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators
    • Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Strode 1999; 30: 1223-9.
    • (1999) Strode , vol.30 , pp. 1223-1229
    • Hart, R.G.1    Pearce, L.A.2    McBride, R.3    Rothbart, R.M.4    Asinger, R.W.5
  • 15
    • 0035854054 scopus 로고    scopus 로고
    • Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation
    • Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
    • (2001) JAMA , vol.285 , pp. 2864-2870
    • Gage, B.F.1    Waterman, A.D.2    Shannon, W.3    Boechler, M.4    Rich, M.W.5    Radford, M.J.6
  • 16
    • 0042422040 scopus 로고    scopus 로고
    • A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study
    • Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-56.
    • (2003) JAMA , vol.290 , pp. 1049-1056
    • Wang, T.J.1    Massaro, J.M.2    Levy, D.3    Vasan, R.S.4    Wolf, P.A.5    D'Agostino, R.B.6
  • 18
    • 0024543543 scopus 로고
    • Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
    • Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
    • (1989) Lancet , vol.1 , pp. 175-179
    • Petersen, P.1    Boysen, G.2    Godtfredsen, J.3    Andersen, E.D.4    Andersen, B.5
  • 19
    • 0025241137 scopus 로고
    • The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
    • The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators
    • The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-11.
    • (1990) N Engl J Med , vol.323 , pp. 1505-1511
  • 21
    • 0025914693 scopus 로고
    • Stroke prevention in atrial fibrillation study. Final results
    • Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-39.
    • (1991) Circulation , vol.84 , pp. 527-539
  • 22
    • 0026478818 scopus 로고
    • Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
    • Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators
    • Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-12.
    • (1992) N Engl J Med , vol.327 , pp. 1406-1412
    • Ezekowitz, M.D.1    Bridgers, S.L.2    James, K.E.3    Carliner, N.H.4    Colling, C.L.5    Gornick, C.C.6
  • 23
    • 0035835397 scopus 로고    scopus 로고
    • Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation
    • Taylor F, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321-6.
    • (2001) BMJ , vol.322 , pp. 321-326
    • Taylor, F.1    Cohen, H.2    Ebrahim, S.3
  • 24
    • 0028244264 scopus 로고
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
    • Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
    • (1994) Arch Intern Med , vol.154 , pp. 1449-1457
  • 25
    • 0032557174 scopus 로고    scopus 로고
    • Patients with non valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study
    • The SPAF III writing committee for the stroke prevention in atrial fibrillation investigators
    • Patients with non valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III writing committee for the stroke prevention in atrial fibrillation investigators. JAMA 1998; 279: 1273-7.
    • (1998) JAMA , vol.279 , pp. 1273-1277
  • 26
    • 0033539341 scopus 로고    scopus 로고
    • Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumadin with aspirin
    • Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumadin with aspirin. BMJ 1999; 319: 958-64.
    • (1999) BMJ , vol.319 , pp. 958-964
    • Hellemons, B.S.1    Langenberg, M.2    Lodder, J.3    Vermeer, F.4    Schouten, H.J.5    Lemmens, T.6
  • 27
    • 2942696888 scopus 로고
    • Warfarin versus aspirin for prevention of thrombo embolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study
    • Warfarin versus aspirin for prevention of thrombo embolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687-91.
    • (1994) Lancet , vol.343 , pp. 687-691
  • 28
    • 0031852543 scopus 로고    scopus 로고
    • Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study
    • Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158: 1513-21.
    • (1998) Arch Intern Med , vol.158 , pp. 1513-1521
    • Gullov, A.L.1    Koefoed, B.G.2    Petersen, P.3    Pedersen, T.S.4    Andersen, E.D.5    Godtfredsen, J.6    Boysen, G.7
  • 29
    • 5644295138 scopus 로고    scopus 로고
    • Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study
    • NASPEAF Investigators
    • Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44: 1557-66.
    • (2004) J Am Coll Cardiol , vol.44 , pp. 1557-1566
    • Perez-Gomez, F.1    Alegria, E.2    Berjon, J.3    Iriarte, J.A.4    Zumalde, J.5    Salvador, A.6    Mataix, L.7
  • 30
    • 0027505093 scopus 로고
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
    • EAFT (European Atrial Fibrillation Trial) Study Group.
    • Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-62.
    • (1993) Lancet , vol.342 , pp. 1255-1262
  • 31
    • 8244245263 scopus 로고    scopus 로고
    • Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation
    • SIFA (Studio Italiano Fibrillazione Atriale) Investigators
    • Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28: 1015-21.
    • (1997) Stroke , vol.28 , pp. 1015-1021
    • Morocutti, C.1    Amabile, G.2    Fattapposta, F.3    Nicolosi, A.4    Matteoli, S.5    Trappolini, M.6
  • 32
    • 0033527355 scopus 로고    scopus 로고
    • Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
    • Hart RG, Benavente O, Mc Bride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
    • (1999) Ann Intern Med , vol.131 , pp. 492-501
    • Hart, R.G.1    Benavente, O.2    Mc Bride, R.3    Pearce, L.A.4
  • 35
    • 0034153308 scopus 로고    scopus 로고
    • Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center
    • Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000; 85: 568-72.
    • (2000) Am J Cardiol , vol.85 , pp. 568-572
    • Bradley, B.C.1    Perdue, K.S.2    Tisdel, K.A.3    Gilligan, D.M.4
  • 36
    • 0036787538 scopus 로고    scopus 로고
    • Anticoagulants for atrial fibrillation: Why is the treatment rate so low?
    • Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002; 25: 447-54.
    • (2002) Clin Cardiol , vol.25 , pp. 447-454
    • Buckingham, T.A.1    Hatala, R.2
  • 37
    • 0031766144 scopus 로고    scopus 로고
    • A community survey of patients with atrial fibrillation: Associated disabilities and treatment preference
    • Sudlow M, Thomson R, Kenny RA, Rodgers H. A community survey of patients with atrial fibrillation: associated disabilities and treatment preference. Br J Gen Pract 1998; 48: 1775-8.
    • (1998) Br J Gen Pract , vol.48 , pp. 1775-1778
    • Sudlow, M.1    Thomson, R.2    Kenny, R.A.3    Rodgers, H.4
  • 38
    • 2542507510 scopus 로고    scopus 로고
    • Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study
    • The College of French Cardiologists
    • Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, Sebaoun A. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99: 3028-35.
    • (1999) Circulation , vol.99 , pp. 3028-3035
    • Levy, S.1    Maarek, M.2    Coumel, P.3    Guize, L.4    Lekieffre, J.5    Medvedowsky, J.L.6    Sebaoun, A.7
  • 39
    • 0037452274 scopus 로고    scopus 로고
    • Anticoagulation in hospitals and general practice
    • Blann AD, Fitzmaurice DA, Lip GY. Anticoagulation in hospitals and general practice. BMJ 2003; 326: 153-6.
    • (2003) BMJ , vol.326 , pp. 153-156
    • Blann, A.D.1    Fitzmaurice, D.A.2    Lip, G.Y.3
  • 41
    • 33646060220 scopus 로고    scopus 로고
    • Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France
    • in press
    • The FALSTAF Study Group. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. Pharmacoepidemiology and Drug Safety 2005 (in press).
    • (2005) Pharmacoepidemiology and Drug Safety
  • 42
    • 10444278105 scopus 로고    scopus 로고
    • Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis
    • Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126: 1938-45.
    • (2004) Chest , vol.126 , pp. 1938-1945
    • Reynolds, M.W.1    Fahrbach, K.2    Hauch, O.3    Wygant, G.4    Estok, R.5    Cella, C.6    Nalysnyk, L.7
  • 43
    • 0038185371 scopus 로고    scopus 로고
    • Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: A dose-guiding, tolerability, and safety study
    • Petersen P, Grind M, Adler J, Sportif II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41: 1445-51.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1445-1451
    • Petersen, P.1    Grind, M.2    Adler, J.3
  • 44
  • 48
    • 0037028033 scopus 로고    scopus 로고
    • A comparison of rate control and rhythm control in patient with recurrent persistent atrial fibrillation
    • Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patient with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
    • (2002) N Engl J Med , vol.347 , pp. 1834-1840
    • Van Gelder, I.C.1    Hagens, V.E.2    Bosker, H.A.3    Kingma, J.H.4    Kamp, O.5    Kingma, T.6
  • 49
    • 0038025290 scopus 로고    scopus 로고
    • Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The strategies of treatment of atrial fibrillation (Staf) study
    • Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (Staf) study. J Am Coll Cardiol 2003; 41: 1690-6.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1690-1696
    • Carlsson, J.1    Miketic, S.2    Windeler, J.3    Cuneo, A.4    Haun, S.5    Micus, S.6
  • 50
    • 0034715973 scopus 로고    scopus 로고
    • Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial
    • Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.
    • (2000) Lancet , vol.356 , pp. 1789-1794
    • Hohnloser, S.H.1    Kuck, K.H.2    Lilienthal, J.3
  • 51
    • 4143064759 scopus 로고    scopus 로고
    • Rate control vs rhythm control in patient with non valvular atrial fibrillation: The results of the polish How to treat chronic atrial fibrillation (Hot Cafe)
    • Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P et al. Rate control vs rhythm control in patient with non valvular atrial fibrillation: the results of the polish How to treat chronic atrial fibrillation (Hot Cafe). Chest 2004; 126: 476-86.
    • (2004) Chest , vol.126 , pp. 476-486
    • Opolski, G.1    Torbicki, A.2    Kosior, D.A.3    Szulc, M.4    Wozakowska-Kaplon, B.5    Kolodziej, P.6
  • 52
    • 12344268922 scopus 로고    scopus 로고
    • Quality of life in atrial fibrillation: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study
    • Jenkins LS, Brodsky M, Schron E, Chung M, Rocco T Jr, Lader E et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 112-20.
    • (2005) Am Heart J , vol.149 , pp. 112-120
    • Jenkins, L.S.1    Brodsky, M.2    Schron, E.3    Chung, M.4    Rocco Jr., T.5    Lader, E.6
  • 53
    • 19444384304 scopus 로고    scopus 로고
    • Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (Affirm) study
    • Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (Affirm) study. Arch Intern Med 2005; 165: 1185-91.
    • (2005) Arch Intern Med , vol.165 , pp. 1185-1191
    • Sherman, D.G.1    Kim, S.G.2    Boop, B.S.3    Corley, S.D.4    Dimarco, J.P.5    Hart, R.G.6
  • 54
    • 0035282120 scopus 로고    scopus 로고
    • Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation
    • Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001; 37: 691-704.
    • (2001) J Am Coll Cardiol , vol.37 , pp. 691-704
    • Klein, A.L.1    Murray, R.D.2    Grimm, R.A.3
  • 55
    • 0035837496 scopus 로고    scopus 로고
    • Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
    • Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344: 1411-20.
    • (2001) N Engl J Med , vol.344 , pp. 1411-1420
    • Klein, A.L.1    Grimm, R.A.2    Murray, R.D.3    Apperson-Hansen, C.4    Asinger, R.W.5    Black, I.W.6
  • 56
    • 10744225802 scopus 로고    scopus 로고
    • Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) trial
    • ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group
    • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P et al. ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003.
    • (2004) Circulation , vol.109 , pp. 997-1003
    • Stellbrink, C.1    Nixdorff, U.2    Hofmann, T.3    Lehmacher, W.4    Daniel, W.G.5    Hanrath, P.6
  • 57
    • 0345414673 scopus 로고    scopus 로고
    • Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (Sportif III): Randomised controlled trial
    • Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (Sportif III): randomised controlled trial. Lancet 2003; 362: 1691-8.
    • (2003) Lancet , vol.362 , pp. 1691-1698
    • Olsson, S.B.1
  • 58
    • 13444309949 scopus 로고    scopus 로고
    • Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial
    • Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S et al.; Sportif Executive Steering Committee for the Sportif V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8.
    • (2005) JAMA , vol.293 , pp. 690-698
    • Albers, G.W.1    Diener, H.C.2    Frison, L.3    Grind, M.4    Nevinson, M.5    Partridge, S.6
  • 59
    • 4444382665 scopus 로고    scopus 로고
    • Novel antithrombotic agents: Indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies
    • Leone G, Rossi E, Leone AM, De Stefano V. Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 311-26
    • (2004) Curr Med Chem Cardiovasc Hematol Agents , vol.2 , pp. 311-326
    • Leone, G.1    Rossi, E.2    Leone, A.M.3    De Stefano, V.4
  • 60
    • 3142722603 scopus 로고    scopus 로고
    • Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: The Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study
    • Lorenzoni R, Lazzerini G, Cocci F, De Caterina R. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J 2004; 148: 6.
    • (2004) Am Heart J , vol.148 , pp. 6
    • Lorenzoni, R.1    Lazzerini, G.2    Cocci, F.3    De Caterina, R.4
  • 61
    • 0141613021 scopus 로고    scopus 로고
    • Combined Antiplatelet Therapy in Atrial Fibrillation: Review of the literature and future avenues
    • Hohnloser SH, Connolly SJ. Combined Antiplatelet Therapy in Atrial Fibrillation: review of the literature and future avenues. J Cardiovasc Electropnysiol 2003; 14 (Suppl 9): S60-3.
    • (2003) J Cardiovasc Electropnysiol , vol.14 , Issue.SUPPL. 9
    • Hohnloser, S.H.1    Connolly, S.J.2
  • 62
    • 20044369896 scopus 로고    scopus 로고
    • Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study
    • Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-19.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 712-719
    • Wachtell, K.1    Lehto, M.2    Gerdts, E.3    Olsen, M.H.4    Hornestam, B.5    Dahlof, B.6
  • 63
    • 20044388522 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study
    • Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705-11.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 705-711
    • Wachtell, K.1    Hornestam, B.2    Lehto, M.3    Slotwiner, D.J.4    Gerdts, E.5    Olsen, M.H.6
  • 64
    • 7744220366 scopus 로고    scopus 로고
    • The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: Meta-analysis of randomized controlled clinical trials
    • Madrid AH, Peng J, Zamora J, Marin I, Bernal E, Escobar C et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-10.
    • (2004) Pacing Clin Electrophysiol , vol.27 , pp. 1405-1410
    • Madrid, A.H.1    Peng, J.2    Zamora, J.3    Marin, I.4    Bernal, E.5    Escobar, C.6
  • 65
    • 20344396863 scopus 로고    scopus 로고
    • Prevention of atrial fibrillation with angiotensin-converting enzyme Inhibitors and angiotensin receptor blockers: A meta-analysis
    • Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme Inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 1832-1839
    • Healey, J.S.1    Baranchuk, A.2    Crystal, E.3    Morillo, C.A.4    Garfinkle, M.5    Yusuf, S.6    Connolly, S.J.7
  • 66
    • 2642536741 scopus 로고    scopus 로고
    • Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents?
    • Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: 1118-26.
    • (2004) Circulation , vol.109 , pp. 1118-1126
    • Schonbeck, U.1    Libby, P.2
  • 67
    • 0242572150 scopus 로고    scopus 로고
    • Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion
    • Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-5.
    • (2003) Am J Cardiol , vol.92 , pp. 1343-1345
    • Siu, C.W.1    Lau, C.P.2    Tse, H.F.3
  • 68
    • 0346996797 scopus 로고    scopus 로고
    • Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease
    • Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-83.
    • (2003) Am J Cardiol , vol.92 , pp. 1379-1383
    • Young-Xu, Y.1    Jabbour, S.2    Goldberg, R.3    Blatt, C.M.4    Graboys, T.5    Bilchik, B.6    Ravid, S.7
  • 69
  • 70
    • 21344473932 scopus 로고    scopus 로고
    • Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: Results from the international multi-center feasibility trials
    • Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC, Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005; 46: 9-14.
    • (2005) J Am Coll Cardiol , vol.46 , pp. 9-14
    • Ostermayer, S.H.1    Reisman, M.2    Kramer, P.H.3    Matthews, R.V.4    Gray, W.A.5    Block, P.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.